The identification of driver oncogenes has provided important targets for drugs that can
change the landscape of cancer therapies. One such example is the BRAF oncogene, which …

In August 2011 vemurafenib (Zelboraf; Daiichi Sankyo/Roche), an inhibitor of BRAF kinase,
was approved by the US Food and Drug Administration (FDA) for the treatment of patients …

BRAF V600 mutations occur in a wide range of tumor types, and RAF inhibition has become
standard in several of these cancers. Despite this progress, BRAF V600 mutations have …

After decades of stagnation, recent therapeutic advances in melanoma seem on the horizon.
The discovery of the genetic underpinnings of this historically refractory disease has …

The discovery of activating BRAF mutations in∼ 50% of all melanomas has proved to be a
turning point in the therapeutic management of the disseminated disease. In this …

Background Mutations in BRAF were first reported in 2002. Since that time, the molecular
basis for oncogenic signaling has been elucidated in multiple malignancies. The …

Vemurafenib is the first molecularly targeted therapy to be licensed in the US and Europe for
treatment of advanced melanoma. Its mechanism of action involves selective inhibition of the …

Melanoma is the most aggressive form of skin cancer. The treatment of patients with
advanced melanoma is rapidly evolving due to an improved understanding of molecular …

Melanomas frequently harbor BRAFV600 mutations. Vemurafenib (RG7204/PLX4032), a
small-molecule inhibitor of mutant BRAF, has shown striking clinical efficacy in BRAFV600 …

Activating BRAF mutations, leading to constitutive activation of the MAPK signaling pathway,
are common in a variety of human cancers. Several small molecule BRAF inhibitors have …